Chandra Briggman

According to the latest report from Rock Health, digital health funding in Q1 2024 totaled $2.7B across 133 deals, with an average deal size of $20.6M. It doesn’t break out device-related investments, but most medtech founders I meet these days are being forced to chase tiny rounds made up of endless little checks, consuming valuable energy and slowing their progress. The benign neglect of this next generation of diagnostic and therapeutic devices is counterproductive and surprising. Given the crowded virtual care market, for example, I’d expect more such companies would be exploring medtech partnerships, investments or acquisitions that'd enable them to back integrate into delivering sharper, and more differentiated, care and treatment. This is exactly what Maverix Medical is doing from the other direction: Reshaping the entire spectrum of lung cancer care by integrating more advanced + effective approaches to screening and diagnosis, treatment and therapeutics, and even palliative care…And putting it all to work through an innovative provider network. One notable investor exception is Y Combinator partner Surbhi Sarna who’s been backing great teams like Selera Medical (YC W24) doing foundational work on ambitious medical devices. Without more support from investors like her, we’re going to increasingly find ourselves stuck with the incremental portfolio improvements from the incumbents, and that’s just not nearly enough.

58

5 Comments

The healthcare landscape is rapidly evolving, driven by advancements in technology and a deeper understanding of patient care. I had the pleasure of speaking with Ambar Bhattacharyya, Co-Managing Partner at Maverick Ventures, on the latest episode of The Full Ratchet. Ambar has partnered with numerous billion-dollar companies like hims & hers, Cityblock Health, Devoted Health, and ConcertAI. His unique journey from rural America to becoming a prominent figure in venture capital offers invaluable insights into the future of healthcare and technology. We discuss his investment strategy at Maverick Ventures, the megatrends shaping healthcare, the impact of AI on the industry, and the importance of integrated care. Ambar also shares his thoughts on the challenges and opportunities in healthcare investment, offering a comprehensive view of what lies ahead. Check out TFR Episode 438 to catch our conversation. You'll be glad you listened.

117

8 Comments

Today marks a groundbreaking moment for BLCK VC and our fellow collaborators—Diversity VC, All Raise, 2Gether-International, SomosVC, StartOut, and VetsinTech—as we proudly announce the launch of the Diversity Data Alliance. This important alliance underscores our unwavering commitment to nurturing a venture capital and entrepreneurial ecosystem abundant in equity and inclusiveness. By standardizing and linking our data, we empower ourselves with the essential tools to track deeper trends that have, until now, eluded us to identify and fill funding gaps for historically excluded investors, founders, and operators. We can’t change what we do not measure, and now with the Diversity Data Alliance, we're now equipped to do both. Join us in this mission. Learn more and get involved: https://lnkd.in/eEZKdrac #DiversityDataAlliance #BLCKVC #VentureCapital #MeasureToChange

112

1 Comment

Some great advice in this interview — featuring Jeffry Weinhuff of Visionary Ventures — relevant to all sub-sectors of #medtech. My favorite line is “investment capital is not tuition.” 😂 But the best advice stems from the insight that good exits via IPO or M&A processes with multiple buyers competing for your company require that most medtech companies must prove their value via strong commercial metrics. And doing that takes a lot of time, expertise and money. Plan, hire and raise capital accordingly. At Vensana Capital, our investment process centers on a deep analysis of every aspect of getting a breakthrough medtech innovation to market, no matter what stage of development a company is at today. We like entrepreneurs who believe their innovation can be highly impactful to patients. We love the ones who want to leave no doubt. https://lnkd.in/eDsUqgn6

81

1 Comment

As the discourse shifts from models to compound AI systems / agents, we need better AI benchmarks to evaluate multi-modal and multi-step task performance, especially in healthcare and life sciences. When we wrote the first paper demonstrating ChatGPT's performance on the USMLE, we chose the US Medical Licensing Exam as a benchmark for accessibility, speed, and ease. This benchmark was never intended to represent AI model performance on real-world clinical tasks. Today, I still see so many research teams and startups using benchmarks (like the USMLE) that are ill-fitted for assessing the true clinical or scientific performance and utility of the models they are developing for real-world contexts. Benchmark development may be seen as a "less sexy" area of research, but it is of paramount importance. Years after the rise of the transformer, we still lack adequate benchmarks for so many single-step tasks in biomedicine. With compound AI systems (i.e., architectures that integrate multiple AI models to perform complex tasks) emerging, we need new benchmarks for agentic behaviors. I'd argue that developing an agent with novel capabilities without at least proposing a companion benchmark (if an industry standard does not yet exist) may hinder the adoption of said agent, especially for high-stakes workflows. Designing more benchmarks that capture/simulate real-world clinical and scientific workflows will help us mitigate the major discrepancies observed between in silico and in vivo performance and better support safe + effective deployment of AI in biomedicine. There are already brilliant people focused here, and we need more. DMs are open if you're researching or working in this area of multi-step/multi-modal benchmarking in healthcare and life sciences! #healthcare #ai #artificialintelligence #generativeai

100

18 Comments

Like Secretariat at Belmont, the US is waaaay ahead. From the Stanford Institute for Human-Centered Artificial Intelligence (HAI)’s AI Index. Worth checking out. https://lnkd.in/evqyk7T3 #vc #venturecapital #startups #entrepreneurs #entrepreneurship #tech #technology #innovation #deeptech #ai #artificialintelligence #money #business

522

60 Comments

Check out the podcast below to learn more about Vivodyne and it's CEO & Co-Founder, Andrei Georgescu, Ph.D. on how they are de-risking drug development with their novel organ-on-a-chip technology.

6

Abby Levy talks about venture's role in US healthcare and what we can expect to see as technology impacts the space on TFR. Check out the rest of the conversation with Abby & Alan Patricof of Primetime Partners on Episode 433.

31

6 Comments

On the latest Vital Signs, Nikhil Krishnan and I had a ton of fun chatting with Dr. Atul Butte. Dr. Butte is a professor at UCSF, Chief Data Scientist of the UC Health System, and a co-founder of numerous healthcare startups. In our conversation, Dr. Butte shared his takes on healthcare AI opportunities, challenges, hype, and more. A few highlights: ⚡LLM use cases, data, and growth LLMs are already helping to solve the “drudgery” aspects of medicine, such as automatically drafting SOAP notes and patient messages. Dr. Butte is excited about future applications of LLMs that can help with the “cognitive” aspects: with difficult medical problems an LLM might be able to stitch together disparate pieces of information to generate a potentially novel solution. He also highlights that prompt engineering will become the next “coding language” as so much of leveraging LLMs is knowing how to ask them the right questions. Additionally, Dr. Butte discusses how since 2016, UCSF has been working to deidentify its patient notes so that it can query them to answer clinical questions and ultimately enhance patient care. ⚡The need for patient-facing AI As patients are increasingly able to access their own personal health data in nicely structured formats (e.g., EHRs, wearables), they desperately need more tools to help them interpret and make decisions using that data. Dr. Butte understands that these patient-facing solutions are challenging to get funded but he emphasizes that patients need to receive the benefits of AI sooner. ⚡Evaluating healthcare AI solutions In order to evaluate AI solutions, we often put human specialists – such as medical professionals – on the same tasks. Understanding that specialists often disagree with each other, a significant challenge arises in figuring out how we can evaluate AI considering we can’t just “average” all the specialist opinions. Dr. Butte points out that there still remains a massive gap in AI evaluation tools. Additionally, there are so many organizations that want to have a say in how healthcare AI is regulated that the landscape is uncertain. An awesome conversation with an expert on all things AI meets healthcare. Listen to the full episode below: Spotify: https://spoti.fi/3Wr3643 Apple: https://apple.co/4acwgan

82

8 Comments

What do you do when a radical new technology puts your main product right in the crosshairs of disruption? Listen to David Okuniev — co-founder of Typeform | Ask awesomely — discuss the challenges of innovation within existing structures. David shared a game-changing insight: Radical innovation is really, really difficult to do inside your own product. He emphasized the need to break free from the constraints of familiarity and embrace change from outside the box. Henrik Werdelin and I have both seen our fair share of this in our respective careers. What struck us most was how David leveraged structure to overcome the innovator’s dilemma. By creating a culture of experimentation and providing space for bold ideas, he propelled Typeform beyond incremental improvements. What other hacks have you seen or employed to help your organization overcome the innovator’s dilemma? Share your stories below! 👇 And if you want to dive deeper into our conversation, click the link in the comments to catch the full podcast episode!

4

2 Comments

I'm looking forward to speaking at this conference on the confluence of law, tech, advocacy and policy and how new innovation centers like the Berkeley Space Center can reinvent the way we tackle hard problems. Berkeley Center for Law and Business, #gobears

12

🚀 Attention Investors and Healthcare Leaders! 🚀 R3i are thrilled to celebrate StratifiCare™ Pte. Ltd.'s CEO, Anthony Chua, who just landed in Dallas, Texas, to accelerate the progress of two revolutionary personalized medicine diagnostics: 🌟 Stratifiden - The world's first severe dengue prognostic that reduces unnecessary hospitalization by 67%, easing the emotional and financial burden on families. 🌟 Stratifirey - The world's first liver cancer diagnostic that predicts patient response to Y90 RE treatment, allowing clinicians to make informed decisions and reduce the agonizing 3 to 6-month wait for results. StratifiCare's journey is a testament to perseverance and innovation. To develop these groundbreaking products, it secured $35M in non-dilutive capital and less than $1M in venture capital. Anthony Chua's unwavering determination teaches us the power of persistence and the impact of every step forward. A special thank you to David Jacobson for welcoming StratifiCare™ Pte. Ltd. into our Texas triangle and the SMU Cox School of Business community. 💡 Investors and hospital administrators, this is your chance to be part of a transformative journey in personalized medicine. Reach out and learn how you can support and benefit from these pioneering advancements. Together let's accelerate impact 💡 NUS Overseas Colleges National University of Singapore Singapore Economic Development Board (EDB) #HealthcareInnovation #PersonalizedMedicine #DengueDiagnostic #LiverCancerDiagnostic #StratifiCare #InvestmentOpportunities #HealthcareLeaders #MedicalBreakthroughs #Valuebasedcare Enterprise Singapore

25

In the quickly evolving landscape of AI, there are few people that possess the depth of experience and insight as our advisor Jia Li. We recently sat down with her to break down: *The mistake founders often make around quality of data, especially in healthcare *How learning from human behavior can help founders better align their expectations *Why she sees the current “Gen AI era" as particularly transformative

93

One key reason why healthcare technologies like AI, telemedicine, and software haven't structurally lowered costs or broadened access for the entire system after decades of experimentation (excluding pure financial engineering of payer contracts) is the limited reimagining of care delivery itself, with asynchronous telemedicine as a notable exception. In the same way that digitizing physical paper failed to exploit the capabilities of a new computing medium for word processing, hosting physician-patient conversations over video does not transform the actual delivery of care. In telemedicine, many of the inputs (e.g., clinician time) and therefore cost structures of in-person care persist, which is why we often see fee-for-service telemedicine companies struggle to achieve economies of scale (i.e., growing revenues non-linearly while growing costs linearly). Until we deconstruct the components of a medical appointment – from intake and triage, to chart review, history gathering, physical examination, diagnosis, treatment, and follow-up – we will continue to be underwhelmed by the disconnect between the transformative potential of these technologies and real-world patient/system impact. I’m optimistic that the emergence of reliable and performant medical AI agents will urge us to perform this deconstruction and redesign the fundamental building blocks of a “medical appointment.”

215

39 Comments

While the healthcare funding landscape shifts, opportunity persists. Our post details the Top 9 VC firms focusing on transformative healthcare investments in 2024. A must-read for startups poised to navigate these changes and emerge successfully. #HealthTech #VCInsights #HealthcareVC #InnovateHealth

5

The latest data from Crunchbase is a bit of an eyebrow raiser. It’s hypetown on #AI, yet healthcare and biotech emerged as frontrunners in Q1 2024 (24% of the total $66B), emphasizing a shift to sectors that directly impact human health and well-being. #BioTech notables are Mirador Therapeutics (medicine development for immune deficiencies), Diagonal Therapeutics (antibody therapies), and Alterome Therapeutics, Inc Therapeutics (treating oncological diseases). #Healthtech

11

2 Comments

Last week I had the pleasure of being on The Exit, which is hosted by Steve McGarry and presented by Flippa.com. In this episode, I talk about my exits from MeMD and NextCare. At the end of the episode, I discuss how I time my ventures and how I live life as a serial entrepreneur. #businessexit #exitstrategy #entrepreneur #businesstips #healthcareleadership

46

1 Comment

Wilmington North Carolina USA is #1 Startup Ecosystem in the WORLD for small cities under 300,000 people #2 in North Carolina behind an ecosystem that is 40 years old #22 in the USA no matter what size population #61 in the WORLD and the fastest climb up the rankings by moving up 32 spots  in StartupBlink #WilmingtonNC #startup #entrepreneur #investor #NorthCarolina

106

10 Comments